The U.S. Food and Drug Administration has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A, a rare and life-threatening bleeding disorder, Sanofi - Aventis Groupe said in a statement.
The FDA decision date for efanesoctocog alfa, an investigational factor VIII therapy, is set for February 28, 2023.
The Priority review is based on pivotal data from the XTEND-1 Phase 3 study. The study results demonstrated efanesoctocog alfa's ability to reduce annualized bleeding rates, which supports its potential as a therapy with best-in-disease efficacy.
Sanofi and Sobi collaborate on the development and commercialization of efanesoctocog alfa.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.